专家简介——贾伟 2019-10-12T06:29:15+00:00

贾伟

夏威夷大学癌症中心终身教授,癌症生物学项目负责人,代谢组学共享资源研究中心主任。

贾伟教授曾担任天津大学药学院执行副院长,上海交通大学药学院研究副院长。2008年起在格林斯博罗的北卡罗莱纳大学任全职教授, 2013年加入夏威夷大学癌症中心,担任代谢组学共享资源研究中心主任,,同时也是联合国大学基因转化生物医学研究中心的联席主任。

 

主要研究方向

贾博士的研究领域包括碳源代谢及其在癌细胞中的调控,肠道微生物-宿主共同代谢中断与代谢紊乱和胃肠道癌症相关分子机制;内脏-肝-脑轴复杂的代谢相互作用以及癌细胞代谢的调控。

贾教授是公认的代谢组学顶尖科学家。在过去的13年里,他的实验室开发了大量的代谢组学技术和方案,重点是对来自实验动物和人体的血液、尿液、唾液以及组织的内源性小分子代谢物和微量元素进行定量分析。其中许多技术已应用于临床和转化医学研究,包括:

(1)无偏见的代谢分析和数据挖掘、代谢物注释和生物解释,采用高灵敏度、高通量的LC-MS-MS和GC-MS平台;

(2)利用葡萄糖、胆酸盐等同位素标记的常见底物对代谢率和代谢途径进行靶向定量分析;

(3)根据疾病表型的独特代谢特征和患者分层、个性化治疗的生物标志物进行疾病表型的分类和预测;

(4)描述膳食和多组分中草药宿主肠道微生物共同代谢的新方法,如多药代动力学和肠道微生物代谢组学。

 

主要科研项目

1. W. Jia, Principal Investigator NIH/NCI 1U01CA188387-01A1 “Gut microbiota mediated bile acid alterations in hepatic carcinogenesis” 08/01/15 – 07/31/20

2. W. Jia, Co-Investigator (PI: Brouwer) NIH/NIGMS 2R01GM041935 – 22 / P140RO “Altered hepatic disposition of anionic drugs-mechanisms” 09/01/14 – 8/31/19

3. W. Jia, Co-Investigator (PI: Holcombe) NIH/NCI P30 CA071789 “Cancer Center Support Grant (CCSG): University of Hawaii Cancer Center” 07/01/12 – 08/31/17

4. W. Jia, Co-Investigator (PI: Cheng) NIH/NCI 1 P01 CA154295-01A1 “Chinese Herbal Medicine as a Novel Paradigm for Cancer Chemotherapy” 04/01/12 – 03/31/17

5. W. Jia, Principal Investigator Nestle Institute of Health Sciences Ltd. Award 007184-00002 “Microbiome metabonomics: monitoring mammalian – gut microbial co- metabolism in human plasma, urine and stools” 03/01/15 – 02/28/17

主要论著(*为通讯作者)

1.Chen, WL, Wang, YY, Zhao, AH, Xia, L, Xie, GX, Su, MM, Zhao, LJ, Liu, JJ, Qu, C, Wei, RM, Rajani, C, Ni, Y, Cheng, Z, Chen, Z, Chen, SJ, Jia, W. (2016). Enhanced fructose utilization mediated by SLC2A5 is a unique metabolic feature of acute myeloid leukemia with therapeutic potential, Cancer Cell, 30(5), 779-791, 2016. PMID: 27746145

2.Xie, GX, Wang, XN, Huang, FJ, Zhao, AH, Chen, WL, Yan, JY, Zhang, YJ, Lei, S, Ge, K, Zheng, XJ, Liu, JJ, Su, MM, Liu, P, Jia, W. (2016). Dysregulated hepatic bile acids collaboratively promote liver carcinogenesis. International Journal of Cancer, 139(8), 1764-1775. PMID: 27273788

3.Qiu YP, Cai GX, Zhou BS, Li D, Zhao AH, Xie GX, Li HK, Cai SJ, Xie D, Huang CZ, Ge WT, Zhou ZX, Xu L, Jia WP, Zheng S, Yen Y, Jia W. (2014). A distinct metabolic signature of human colorectal cancer with prognostic potential, Clinical Cancer Research, 20(8), 2136-2146. PMID: 24526730

4.Zheng XJ, Zhao AH, Xie GX, Chi Y, Zhao LJ, Li HK, Wang CR, Bao YQ, Jia WP, Luther M, Su MM, Nicholson JK, Jia W. (2013). Melamine-Induced renal toxicity is mediated by the gut microbiota. Science Translational Medicine, 5(172):172ra22. PMID:23408055

5.Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, Jia W, Pettersson S. (2012). Host-gut microbiota metabolic interactions. Science, 336(6086): 1262-7. PMID:22674330

6.Jia W, Li HK, Zhao LP, Nicholson JK. (2008). Gut microbiota: a potential new territory for drug targeting. Nature Reviews Drug Discovery, 7(2):123-9. PMID:18239669